ArticleCell reports. Medicine2023
Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs.
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.Oncogene · 2026Article
- Brain metastases converge on shared geometric architecture and transcriptomic landscape yet remain distinct from gliomas.iScience · 2026Article
- Global impact of germline structural variation on the cancer proteome.Nature communications · 2026Article
- PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells.bioRxiv : the preprint server for biology · 2026Article
- Integrative analyses of metastatic cancer transcriptome reveal clinically distinct cellular States and ecosystems.Scientific reports · 2026Article
- Identification of Clinically Relevant Genes Using Machine Learning Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
- Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives.Cells · 2025Review
- Pan-cancer, multi-omic correlates of survival transcending tumor lineage across 11,019 patients reveal targets and pathways.NPJ precision oncology · 2025Article
- Pan-cancer analysis shapes the understanding of cancer biology and medicine.Cancer communications (London, England) · 2025Review
- Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination.Nature genetics · 2025Article
- Pan-cancer drivers of metastasis.Molecular cancer · 2025Article
- SMARCD1 is an essential expression-restricted metastasis modifier.Communications biology · 2024Article
- An essential gene signature of breast cancer metastasis reveals targetable pathways.Breast cancer research : BCR · 2024Article
- Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.Cancer biology & medicine · 2024Article
- SMARCD1 is a "Goldilocks" metastasis modifier.bioRxiv : the preprint server for biology · 2024Article
- Global impact of somatic structural variation on the cancer proteome.Nature communications · 2023Article
- Article
- Using cancer proteomics data to identify gene candidates for therapeutic targeting.Oncotarget · 2023Article
- Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Molecular mechanisms underlying cancer metastasis span diverse tissues of origin. Here, we synthesize and collate the transcriptomes of patient-derived xenografts and patient tumor metastases, and these data collectively represent 38 studies and over 3,000 patients and 4,000 tumors. We identify four expression-based subtypes of metastasis transcending tumor lineage. The first subtype has extensive copy alterations, higher expression of MYC transcriptional targets and DNA repair genes, and bromodomain inhibitor response association. The second subtype has higher expression of genes involving metabolism and prostaglandin synthesis and regulation. The third subtype has evidence of neuronal differentiation, higher expression of DNA and histone methylation genes and EZH2 transcriptional targets, and BCL2 inhibitor response association. The fourth subtype has higher expression of immune checkpoint and Notch pathway genes. The metastasis subtypes reflect expression differences from paired primaries, with subtype switching being common. These subtypes facilitate understanding of the molecular underpinnings of metastases beyond tissue-oriented domains, with therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.